cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
United Therapeutics Corporation
17 own
15 watching
Current Price
$346.2
$3.74
(1.09%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
11,927.01M
52-Week High
52-Week High
366.07999
52-Week Low
52-Week Low
208.62000
Average Volume
Average Volume
0.38M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
20.825
iconMarket Capitalization11,927.01M
icon52-Week High366.07999
icon52-Week Low208.62000
iconAverage Volume0.38M
iconDividend Yield--
iconP/E Ratio20.825
What does the United Therapeutics Corporation do?
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's product candidates include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, a once-daily PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy. In addition, the company develops RemoSynch and RemUnity delivery systems for intravenous and subcutaneous Remodulin; esuberaprost and eNOS gene therapies for PAH; and organ transplantation-related technologies, including regenerative medicines, xenotransplantation, and ex-vivo lung perfusion. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Read More
How much money does United Therapeutics Corporation make?
News & Events about United Therapeutics Corporation.
Ticker Report
1 year ago
United Therapeutics Co. (NASDAQ:UTHR Get Rating) EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, March 16th. The shares were sold at an average price of $214.39, for a total transaction of $1,286,340.00. Following the sale, the ...
Zolmax
1 year ago
United Therapeutics Co. (NASDAQ:UTHR Get Rating) CEO Martine A. Rothblatt sold 8,000 shares of the stock in a transaction dated Friday, February 24th. The stock was sold at an average price of $249.27, for a total transaction of $1,994,160.00. Following the transaction, the chief executive officer ...
Zolmax
1 year ago
Shares of United Therapeutics Co. (NASDAQ:UTHR Get Rating) have been given an average rating of Moderate Buy by the thirteen analysts that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating and eight have issued a buy rating on the ...
Zolmax
1 year ago
Shares of United Therapeutics Co. (NASDAQ:UTHR Get Rating) have received an average rating of Moderate Buy from the thirteen brokerages that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, eight have given a buy rating and one ...
Ticker Report
1 year ago
United Therapeutics Co. (NASDAQ:UTHR Get Rating) CEO Martine A. Rothblatt sold 8,000 shares of the companys stock in a transaction on Friday, January 27th. The stock was sold at an average price of $260.01, for a total transaction of $2,080,080.00. Following the completion of the ...
Frequently Asked Questions
Frequently Asked Questions
What is United Therapeutics Corporation share price today?
plus_minus_icon
Can Indians buy United Therapeutics Corporation shares?
plus_minus_icon
How can I buy United Therapeutics Corporation shares from India?
plus_minus_icon
Can Fractional shares of United Therapeutics Corporation be purchased?
plus_minus_icon
What are the documents required to start investing in United Therapeutics Corporation stocks?
plus_minus_icon
What is today’s traded volume of United Therapeutics Corporation?
plus_minus_icon
What is today’s market capitalisation of United Therapeutics Corporation?
plus_minus_icon
What is the 52-Week High and Low Range of United Therapeutics Corporation?
plus_minus_icon
What percentage is United Therapeutics Corporation down from its 52-Week High?
plus_minus_icon
What percentage is United Therapeutics Corporation up from its 52-Week Low?
plus_minus_icon
Current Price
$346.2
$3.74
(1.09%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Catalent, Inc.
Catalent, Inc.
$59.59
$-0.16 (-0.27 %)
Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc.
$318.97
$-5.24 (-1.62 %)
Acuity Brands, Inc.
Acuity Brands, Inc.
$248.05
$-3.37 (-1.34 %)
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
$474.74
$3.96 (0.84 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Catalent, Inc.
Catalent, Inc.
$59.59
$-0.16 (-0.27 %)
Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc.
$318.97
$-5.24 (-1.62 %)
Acuity Brands, Inc.
Acuity Brands, Inc.
$248.05
$-3.37 (-1.34 %)
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
$474.74
$3.96 (0.84 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00